aclidinium,Tudorza Genuair, Tudorza Pressair

 Classification

Therapeutic: COPD agents

Pharmacologic: anticholinergics

Indications

Long-term maintenance treatment of bronchospasm associated

with COPD, including chronic bronchitis and

emphysema. Not for acute (rescue) use.

Action

Acts as an anticholinergic by inhibiting the M3 receptor

in bronchial smooth muscle. Therapeutic Effects:

Bronchodilation with lessened symptoms of COPD.

Pharmacokinetics

Absorption: 6% systemically absorbed following inhalation.

Distribution: Unknown.

Metabolism and Excretion: Rapidly hydrolyzed;

metabolites are not pharmacologically active. Metabolites

are eliminated in urine (54–65%) and feces (20–

33%). 1% excreted unchanged in urine.

Half-life: 5–8 hr.

TIME/ACTION PROFILE (improvement in

FEV1)

ROUTE ONSET PEAK DURATION

Inhaln within 1 hr 2–4 hr 12 hr

Contraindications/Precautions

Contraindicated in: Hypersensitivity to aclidinium

or any of the excipients; Severe hypersensitivity to milk

proteins.

Use Cautiously in: Narrow-angle glaucoma; Prostatic

hyperplasia or bladder neck obstruction; Severe

hypersensitivity to milk proteins; History of hypersensitivity

to atropine (cross-sensitivity may occur); OB: Use

only if potential benefit justifies potential risk to the fetus;

Lactation: Use cautiously; Pedi: Safety and effectiveness

not established.

Adverse Reactions/Side Effects

CNS: headache. EENT: worsening of narrow-angle

glaucoma. Resp: paradoxical bronchospasm. GU:

urinary retention. Misc: HYPERSENSITIVITY REACTIONS

(including anaphylaxis, angioedema, urticaria, rash,

bronchospasm, or itching).

Interactions

Drug-Drug:qrisk of anticholinergic effects with

other anticholingerics.

Route/Dosage

Inhaln (Adults): One inhalation (400 mcg) twice

daily.

Availability

Dry powder metered-dose inhaler: 400 mcg/actuation.